COMP <GO>
WST vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
West Pharmaceutical Services Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: WST 3
— LLY 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: WST
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
balance-sheet
19.06
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | 83.64% | -47.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.90% | 32.36% | -14.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.7x | 36.4x | -1.72 | WST | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 2.30% | -0.70 | LLY | /fcf-yield <GO> |
| Operating Margin | 19.00% | 40.21% | -21.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 31.90% | -15.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.30% | 45.51% | -39.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 0.49% | -0.28 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 19.06 | 9.29 | +9.77 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.3 | 77.9 | -2.55 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | WST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | 26.3x | +28.95 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | LLY REV | WST GROSS % | LLY GROSS % | WST FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $65.18B | 35.9% | 83.0% | $468.9M | $16.81B |
| FY 2024 | $2.89B | $45.04B | 34.5% | 81.3% | $276.4M | $8.82B |
| FY 2023 | $2.95B | $34.12B | 44.0% | 79.3% | $643.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
LLY // BETA 0.51